Mr Anil Pooran
| Call | Career Development Fellowship (CDF) |
| Programme | EDCTP2 |
| Start Date | 2021-01-01 |
| End Date | 2023-12-31 |
| Project Code | TMA2019CDF-2780 |
| Status | Active |
Title
Approaches to investigate pharmacokinetic mismatch and its effect on resistance acquisition in M. tuberculosis
Host Organisation
| Institution | Country |
|---|---|
| The University of Cape Town Lung Institute (Pty) Ltd | South Africa |
Current Organisation
Unniversity of Cape Town Lung Institute
Current Job Title
Senior Research Officer
Students Supervised
| Type | Name | Title | University | Start Date | End Date |
|---|---|---|---|---|---|
| MSc | Lauren Knight | Dr | University of Cape Town | 2016 | 2017 |
| PhD | Ju-Wi Chang | Dr | University of Cape Town | 2015 | 2020 |
| MMed | Khanyisile Dladla | Dr | University of Cape Town | 2020 | 2021 |
Memberships
| Role | Committee/board | Start Date | End Date |
|---|
Education
| Institution | Degree | Year |
|---|---|---|
| University of Cape Town, South Africa | PhD | 2015-06-01 |
| London School of Hygiene and Tropical Medicine, United Kingdom | MSc | 2005-06-01 |
| University of Toronto, Canada | BSc Honours | 2003-06-01 |
Areas Of Specialisation
Tuberculosis (TB)
Grants
Publications
Projects
Fellow:
Anil Pooran
Collaborators:
| Name | Country | Institution |
|---|---|---|
| Keertan Dheda | South Africa | UCT Lung Institute |
| Taane Clark | United Kingdom | LSHTM |
Objectives:
Aim 1: To investigate pharmacokinetic (PK) mismatch within TB cavities obtained from resected lungs of incurable TB patients undergoing surgery (n=30) by determining the concentrations of the WHO group A, B and C drugs (bedaquiline, delaminid, linezolid, clofazimine) at distinct biopsy points across these cavities and their relationship to genotypic and phenotypic MIC’s at the same points and in serial sputum samples
Aim 2: To evaluate targeted deep sequencing for the detection of micro-heteroresistant populations in the sputum relative the site of disease (epithelial lining fluid, lung biopsies from cavity tissue; See Figure 2) in incurable TB patients undergoing lung resection (n=20).
Sites:
Cape Town, South Africa
Study Design:
Prospective cohort
Subjects:
30
Outcomes:
Aim 1 primary outcome measure: TB drug specific concentrations at anatomically distinct points in TB cavities and other lesions correlated to MICs at these equivalent points.
Aim 2 primary outcome measure: correlation of genotypic resistance mutations identified in the sputum to those in the lung
Other outcome measures: detection and quantification of TB drug in the exhaled breath of drug resistant TB patients compared to serum and lung tissue (Aim 1.3)
Linked Grant:
EDCTP Clinical Research & Development Fellowship
Start Date:
2021-01-01
End Date:
2021-12-31